Category
9 articles
Private full-body MRI packages are producing incidental findings that arrive in general practice without a clear owner. This article sets out a practical handover and triage framework for UK clinicians, and the consent points private providers should make clear before anyone pays for imaging.
A low unit price can conceal a costly diagnostic pathway. This analysis sets out a practical total-pathway cost model for UK commissioners and clinical teams, showing why the better buy is often the test that produces a timely, actionable result rather than the one with the smallest invoice.
A diagnostic result is an intermediate event, not an endpoint. This article examines the last mile of testing in UK care: how abnormal findings are communicated, owned and safety-netted across primary and secondary care, and why digital portals and AI triage should be judged by closed-loop follow-up rather than result delivery alone.
A diagnostic or health-software product does not stop changing once it reaches routine care. This article examines how post-market problems surface in UK practice, what MHRA and NHS reporting routes require, and why a transparent correction can strengthen rather than undermine clinical trust.
Digital triage and AI symptom checkers are now part of the NHS front door. They can manage demand and surface red flags, but they cannot ask the questions that make a clinical conversation safe. A practical framework for 2026.
A diagnostic can perform well in study conditions and still fail to change care if the route into practice is never designed. This analysis sets out why NICE evaluation, ICB budget silos, pathway ownership and the missing business case remain the real adoption gate — and the questions innovators, clinicians and commissioners should ask in 2026.
Multi-cancer early detection tests are now reachable through private clinics and NHS evaluation studies, and patients increasingly arrive at general practice holding a result they read as reassurance. This analysis unpacks sensitivity, positive predictive value and interval cancers, and sets out the questions that should accompany a 'clear' result before anyone relaxes.
Health-tech marketing is full of reassuring phrases, but confidence should come from evidence rather than vocabulary. This patient-facing guide explains how to check claims, understand UK regulatory and advertising basics, and use a practical checklist before buying a home health device or app.
The 2026 push to place more biomarker testing and chronic disease monitoring in community pharmacies is attractive for access, but access is not the same as clinical readiness. This evidence-first analysis examines which tests are mature enough for everyday care, where validation and equity gaps remain, and how patients and clinicians should judge the next wave of pharmacy diagnostics announcements.